Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine Long-Term Safety in Children with FASD and ADHD
NCT00418262Phase 3Completed
- Sponsor
- University of Oklahoma
- Start
- Aug 2005
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by University of Oklahoma. Started Aug 2005; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00418262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00418262.